We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $610M
1-Year Est. Return 40.86%
This Fund
S&P 500
This Quarter Est. Return
-7.65%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$362M
AUM Growth
-$44.5M
Cap. Flow
-$4.28M
Cap. Flow %
-1.18%
Top 10 Hldgs %
61.36%
Holding
53
New
8
Increased
13
Reduced
15
Closed
17

Top Buys

Rank Stock Value
1
ACHC icon
Acadia Healthcare
ACHC
+$31M
2
ICLR icon
Icon
ICLR
+$19.8M
3
RCKT icon
Rocket Pharmaceuticals
RCKT
+$14M
4
FOLD
Amicus Therapeutics
FOLD
+$9.56M
5
KURA icon
Kura Oncology
KURA
+$8.92M

Top Sells

Rank Stock Value
1
MCK icon
McKesson
MCK
+$17.7M
2
ACCD
Accolade Inc
ACCD
+$10.8M
3
DXCM icon
DexCom
DXCM
+$10.7M
4
CYTK icon
Cytokinetics
CYTK
+$10.2M
5
ZBH icon
Zimmer Biomet
ZBH
+$9.18M

Sector Composition

Rank Sector Weight
1 Healthcare 98.66%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGHT icon
26
Sight Sciences
SGHT
$267M
$3.31M 0.91%
908,847
+377,625
+71% +$1.72M
LIVN icon
27
LivaNova
LIVN
$4.3B
$3.24M 0.9%
70,000
-20,000
-22% -$1.03M
CRBP icon
28
Corbus Pharmaceuticals
CRBP
$170M
$3.19M 0.88%
270,000
+140,000
+108% +$2.35M
ERAS icon
29
Erasca
ERAS
$6.63B
$2.38M 0.66%
947,110
-1,036,900
-52% -$2.84M
SYRE icon
30
Spyre Therapeutics
SYRE
$8.87B
$1.86M 0.51%
+80,000
New +$2.35M
CDNA icon
31
CareDx
CDNA
$1.92B
$1.71M 0.47%
+80,000
New +$1.95M
MURA
32
DELISTED
Mural Oncology
MURA
$1.5M 0.42%
466,822
-103,798
-18% -$366K
FTRE icon
33
Fortrea Holdings
FTRE
$1.85B
$1.03M 0.28%
+55,100
New +$1.07M
RNTX
34
Rein Therapeutics
RNTX
$67.7M
$931K 0.26%
404,979
+32,822
+9% +$99.4K
IMNM icon
35
Immunome
IMNM
$2.52B
$577K 0.16%
54,342
+15,207
+39% +$184K
OKUR
36
OnKure Therapeutics
OKUR
$166M
$548K 0.15%
+63,754
New +$965K
COGT icon
37
Cogent Biosciences
COGT
$6.79B
– –
-410,830
Closed -$4.44M
CRVL icon
38
PUT
CorVel
CRVL
$3.05B
– –
-8,400
Closed -$915K
CYTK icon
39
Cytokinetics
CYTK
$11B
– –
-192,700
Closed -$10.2M
DXCM icon
40
DexCom
DXCM
$27.6B
– –
-160,000
Closed -$10.7M
IMRX icon
41
Immuneering
IMRX
$279M
– –
-190,000
Closed -$473K
MCK icon
42
McKesson
MCK
$98.5B
– –
-35,822
Closed -$17.7M
MRVI icon
43
Maravai LifeSciences
MRVI
$997M
– –
-208,200
Closed -$1.73M
NBIX icon
44
Neurocrine Biosciences
NBIX
$17.7B
– –
-62,000
Closed -$7.14M
OEF icon
45
PUT
iShares S&P 100 ETF
OEF
$19.8B
– –
-29,000
Closed -$6.41M
OVID icon
46
Ovid Therapeutics
OVID
$435M
– –
-729,208
Closed -$860K
FLNA
47
PUT
Filana Therapeutics
FLNA
$43M
– –
-148,900
Closed -$4.38M
SEM
48
DELISTED
Select Medical
SEM
– –
-48,377
Closed -$909K
STTK icon
49
CALL
Shattuck Labs
STTK
$710M
– –
-86,800
Closed -$303K
VKTX icon
50
Viking Therapeutics
VKTX
$4.04B
– –
-48,000
Closed -$3.04M
1
2
3

Similar funds

PL
Pandi LLC Leawood, Kansas $610M AUM 14.97% 1-Year Est. Return
BFC
Blue Fin Capital Warren, Rhode Island $610M AUM 26.46% 1-Year Est. Return
DCM
DGS Capital Management Jersey City, New Jersey $609M AUM 44.78% 1-Year Est. Return
SAM
Strategy Asset Managers Pasadena, California $609M AUM 32.56% 1-Year Est. Return
CBB
Citizens Business Bank Ontario, California $610M AUM 27.86% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
FFWA
FRG Family Wealth Advisors Bellevue, Washington $611M AUM 25.92% 1-Year Est. Return
CIP
Convergence Investment Partners Palm Beach Gardens, Florida $611M AUM 61.48% 1-Year Est. Return

Prosight Management's Q4 2024 Portfolio in Review

As of Q4 2024, Prosight Management held 53 positions worth $362M, down 11% from $406M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Prosight Management's Q4 2024 filing shows 8 new, 13 increased, 15 reduced and 17 closed positions. Its largest new stake was Icon: 85,000 shares worth $17.8M. The largest sale was McKesson, an estimated $17.7M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 94% a quarter earlier, followed by Industrials.

  • Prosight Management's largest Q4 2024 buy was Icon: 85,000 shares worth $17.8M.
  • Prosight Management added most to Acadia Healthcare in Q4 2024, an estimated $31M increase.
  • Prosight Management's biggest Q4 2024 reduction was Zimmer Biomet, cutting an estimated $9.18M.
  • Prosight Management fully exited McKesson in Q4 2024, selling an estimated $17.7M.
  • Prosight Management's ten largest holdings make up 61% of its $362M portfolio in Q4 2024.
  • Prosight Management opened 8 new positions and closed 17 in Q4 2024.
  • Prosight Management's portfolio value fell 11% quarter-over-quarter to $362M.

Based on Prosight Management's 13F filing for Q4 2024, filed 14 Feb 2025.